The majority of experimental atherosclerosis studies evaluating the impact of SGLT2 inhibitors have been performed in apolipoprotein E deficient mice with and without diabetes mellitus [63,64,65,66,67]. This evidence concerns the gene SLC5A2 and atherosclerosis.